Castle Biosciences, Inc. Stock News

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced the publication of a study demonstrating the impact of the DecisionDx-SCC test in guiding adjuvant radiation therapy decision-maki

The average of price targets set by Wall Street analysts indicates a potential upside of 36.2% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable,

Castle Biosciences (CSTL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it t

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle executive management is scheduled to present a company overview at the Leerink Partners Healthcare Crossroads Conference May 29

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Barrettsesophagus--Castle will share three abstracts related to its TissueCypher® test at DDW 2024.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle awarded the “Best Overall Mental Health Solution” in 8th annual MedTech Breakthrough Awards program for IDgenetix® pharmac

The mean of analysts' price targets for Castle Biosciences (CSTL) points to a 36.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amo

Castle Biosciences (CSTL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed thr

Castle Biosciences, Inc. (NASDAQ:CSTL ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR & Corporate Affairs Derek Maetzold - President, CEO, Found

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ACMS--Castle Biosciences will share new data supporting the utility of its DecisionDx®-SCC test at the ACMS Annual Meeting in Phoenix.

Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $1.10 per share a year ago.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences announced its support of key skin cancer advocacy events and initiatives throughout May in honor of Skin Cancer Awareness Month.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will release its financial results for the first quarter ended March 31, 2024, after the close of market on Thursday, May 2, 20

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle recognizes the importance of Esophageal Cancer Awareness Month and is providing its support of key programs and initiatives thr

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--For the second year in a row, Castle's chief financial officer, Frank Stokes, has been selected as a Top 25 CFO of Houston by TOP CFOs